Sosei Co., Ltd., HRA, And Sandoz/Hexal Australia To Conclude Sublicensing Agreement For "Morning After Pill" SOH-075

21 Dec 2005

·www.biospace.com

Collaborate

Tokyo (JCN) Dec 21, 2005 - Japanese biopharmaceutical company Sosei has announced that it and French pharmaceutical Laboratoire HRA Pharma (HRA) have entered into a sublicensing agreement with Sandoz/Hexal Australia, a wholly owned subsidiary of Novartis AG, for the distribution of SOH-075, an oral levonorgestrel emergency contraceptive developed by HRA. Under the agreement terms, Sandoz Hexal will be licensed to distribute SOH-075 in Australia. Orally administered within 72 hours after an unprotected sexual intercourse, the drug can prevent pregnancy.

Organizations

Laboratoire HRA Pharma SA

Novartis AG

Sosei Co. Ltd.

[+1]

Indications

Targets

Drugs

LevonorgestrelTacrolimus

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.